Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EA06
|
| gptkbp:CASNumber |
1492952-76-7
|
| gptkbp:chemicalFormula |
C20H18ClF2N5O
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:genericName |
gptkb:asciminib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Scemblix
|
| gptkbp:indication |
gptkb:Philadelphia_chromosome-positive_chronic_myeloid_leukemia
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
BCR-ABL tyrosine kinase inhibitor
STAMP inhibitor |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache musculoskeletal pain |
| gptkbp:usedFor |
gptkb:chronic_myeloid_leukemia
|
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|